Ionescu Simona Daniela, Sandru V, Leuciuc Elena, Manea Paloma, Burdujan Alina, Tovarniţchi Svetlana, Cosovanu A
Clinica a III-a Medicală Cardiologică I. Enescu, Facultatea de Medicină, Universitatea de Medicină şi Farmacie Gr.T. Popa Iaşi.
Rev Med Chir Soc Med Nat Iasi. 2002 Jan-Mar;106(1):128-31.
By their intervention upon the mechanisms regulating the vascular tone, renal plasma flow and direct actions of chemical structures, angiotensin-converting enzyme (ACE) inhibitors may determine undesirable effects. These effects formed the object of a 5-year retrospective study (1995-1999) carried out at the IIIrd Medical Clinic of Iasi. During this interval ACE inhibitors were administrated to 2178 patients with hypertensive and coronary disorders or heart failure of various causes. Different generations of ACE inhibitors were used, but captopril, enalapril and lysinopril were the most commonly administered. Undesirable effects were recorded in 161 patients (7.3%). The following side-effects, single or associated, were recorded: 38 patients (23.6%) had increasing blood pressure proportional with ACEI dose, 80 patients (49.7%) had decreasing blood pressure at low doses ACEI, 23 patients (14.4%) had kidney failure, 2 patients (1.2%) had both increasing blood pressure and kidney failure, 3 patients (1.9%) had both decreasing blood pressure and kidney failure, 6 patients (3.8%) had dry cough, one patient (0.6%) had kidney failure with decrease blood pressure and allergic dermatitis, 4 patients (2.4%) had allergic dermatitis, and 4 patients (2.4%) had headache, vertigo, paresthesia.
The treatment with ACE inhibitors has to be carefully initiated under strict clinical and biological monitoring, preferably in hospital setting. No drug associations that favor the undesirable effects of ACE inhibitors were reported.
通过干预调节血管张力、肾血浆流量的机制以及化学结构的直接作用,血管紧张素转换酶(ACE)抑制剂可能会产生不良影响。这些影响是在雅西第三医学诊所进行的一项为期5年的回顾性研究(1995 - 1999年)的研究对象。在此期间,对2178例患有高血压、冠状动脉疾病或各种原因引起的心力衰竭的患者使用了ACE抑制剂。使用了不同代的ACE抑制剂,但卡托普利、依那普利和赖诺普利是最常用的。161例患者(7.3%)记录到了不良影响。记录了以下单一或合并出现的副作用:38例患者(23.6%)血压升高与ACEI剂量成正比,80例患者(49.7%)在低剂量ACEI时血压降低,23例患者(14.4%)出现肾衰竭,2例患者(1.2%)既有血压升高又有肾衰竭,3例患者(1.9%)既有血压降低又有肾衰竭,6例患者(3.8%)出现干咳,1例患者(0.6%)出现肾衰竭伴血压降低和过敏性皮炎,4例患者(2.4%)出现过敏性皮炎,4例患者(2.4%)出现头痛、眩晕、感觉异常。
ACE抑制剂治疗必须在严格的临床和生物学监测下谨慎开始,最好在医院环境中进行。未报告有促进ACE抑制剂不良影响的药物联合使用情况。